Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000465912 | SCV000542240 | likely benign | Neurofibromatosis, type 1 | 2025-01-15 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000482669 | SCV000570039 | uncertain significance | not provided | 2023-03-21 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with breast cancer, but also in unaffected controls (Momozawa et al., 2018; Dorling et al., 2021); This variant is associated with the following publications: (PMID: 33471991, 29089047, 30287823) |
Ambry Genetics | RCV002311768 | SCV000663018 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2021-05-26 | criteria provided, single submitter | clinical testing | The c.5888A>G (p.N1963S) alteration is located in exon 39 (coding exon 39) of the NF1 gene. This alteration results from a A to G substitution at nucleotide position 5888, causing the asparagine (N) at amino acid position 1963 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Athena Diagnostics | RCV000482669 | SCV001879400 | uncertain significance | not provided | 2021-04-23 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000482669 | SCV002046137 | uncertain significance | not provided | 2020-03-19 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000465912 | SCV002560922 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004551515 | SCV004751502 | uncertain significance | NF1-related disorder | 2023-12-05 | no assertion criteria provided | clinical testing | The NF1 c.5951A>G variant is predicted to result in the amino acid substitution p.Asn1984Ser. This variant has been reported in the literature as a variant of uncertain significance in patients with cancers (specifically breast and biliary tract cancers; Momozawa et al. 2018. PubMed ID: 30287823; Okawa et al. 2023. PubMed ID: 36243179; alternate nomenclature: NM_000267.3:c.5888A>G (p.Asn1963Ser)). This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD. In ClinVar this variant is classified as uncertain significance by multiple labs. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |